Ildong Pharmaceutical Co., Ltd.

Total Valuation

Ildong Pharmaceutical Co., Ltd. carries a market capitalization of 476.09B, placing it among publicly traded companies globally. Its enterprise value stands at 903.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Ildong Pharmaceutical Co., Ltd. currently has 31.51M shares outstanding.

Valuation Ratios

Ildong Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 23.98. The price-to-sales ratio is 1.46, and the price-to-book ratio stands at 5.83.

Enterprise Valuation

On an enterprise value basis, Ildong Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 36.59 and an EV/FCF ratio of 20.73. The EV/Sales ratio of 1.58 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.59 provides insight into valuation relative to core operating earnings.

Financial Position

Ildong Pharmaceutical Co., Ltd. maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.70, indicating elevated leverage, while an interest coverage ratio of 2.42 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Ildong Pharmaceutical Co., Ltd. posts a return on equity of 28.89 and a return on invested capital of 5.15.

Taxes

Over the trailing twelve months, Ildong Pharmaceutical Co., Ltd. has paid 9.25B in income taxes, reflecting an effective tax rate of 23.22.

Stock Price Statistics

Ildong Pharmaceutical Co., Ltd.'s stock has declined approximately -11.68907% over the past 52 weeks. The 50-day moving average sits at 20,858.40, while the 200-day moving average is 29,103.60.

Income Statement

Over the trailing twelve months, Ildong Pharmaceutical Co., Ltd. generated 572.95B in revenue and converted that into 34.91B in net income, yielding earnings per share of 1,024.45. EBITDA reached 24.70B, while operating income came in at 24.70B.

Balance Sheet

Ildong Pharmaceutical Co., Ltd. holds 59.07B in cash and equivalents against 133.65B in total debt, resulting in a net debt position of 72.18B. Total book value stands at 143.53B, with working capital of -1.63B providing operational flexibility.

Cash Flow

Ildong Pharmaceutical Co., Ltd. produced 17.33B in operating cash flow over the past twelve months. After subtracting -18.44B in capital expenditures, free cash flow totaled -1.11B - equivalent to -37.22 per share.

Margins

Ildong Pharmaceutical Co., Ltd. operates with a gross margin of 39.76, reflecting its pricing power and cost economics. The operating margin of 4.31 and net profit margin of 6.09 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Ildong Pharmaceutical Co., Ltd.'s most recent stock split took place on March 5, 2020 with a 20:21 split ratio.

Scores

Ildong Pharmaceutical Co., Ltd. posts an Altman Z-Score of 3.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.